• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NICE guidelines on anti-tumor necrosis factor therapy for RA.

作者信息

Scott David L, Steer Sophia

机构信息

Department of Rheumatology, King's College Hospital, London, UK.

出版信息

Nat Clin Pract Rheumatol. 2009 Jan;5(1):16-7. doi: 10.1038/ncprheum0964. Epub 2008 Dec 2.

DOI:10.1038/ncprheum0964
PMID:19048006
Abstract
摘要

相似文献

1
NICE guidelines on anti-tumor necrosis factor therapy for RA.英国国家卫生与临床优化研究所关于类风湿关节炎抗肿瘤坏死因子治疗的指南。
Nat Clin Pract Rheumatol. 2009 Jan;5(1):16-7. doi: 10.1038/ncprheum0964. Epub 2008 Dec 2.
2
If it works why can't we have it? Sequential anti-TNF therapy in the UK.如果它有效，我们为何不能采用？英国的序贯抗TNF治疗。
Rheumatology (Oxford). 2010 Dec;49(12):2235-6. doi: 10.1093/rheumatology/keq257. Epub 2010 Aug 4.
3
Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.模拟肿瘤坏死因子-α拮抗剂治疗类风湿关节炎的成本效益：来自英国风湿病学会生物制剂注册处的结果
Rheumatology (Oxford). 2007 Aug;46(8):1345-54. doi: 10.1093/rheumatology/kem115. Epub 2007 Jun 11.
4
Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.抗 TNF 在类风湿关节炎中的剂量调整和估计的经济影响：观察性研究综述。
Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):71-9. doi: 10.1586/14737167.2015.967219. Epub 2015 Jan 2.
5
Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.符合韩国国民健康保险抗肿瘤坏死因子-α治疗报销指南的类风湿性关节炎患者及其与其他指南的比较。
Rheumatol Int. 2015 Nov;35(11):1817-23. doi: 10.1007/s00296-015-3353-7. Epub 2015 Sep 5.
6
Assessing new therapies for RA: defining new expectations for treatment. New therapies in clinical practice: issues of cost and access.评估类风湿关节炎的新疗法：明确治疗的新期望。临床实践中的新疗法：成本与可及性问题。
Am J Manag Care. 1999 Jun;5(8 Suppl):S502-5.
7
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.英国风湿病学会（BSR）和英国卫生与保健优化研究所（BHPR）关于首次生物治疗资格标准的类风湿性关节炎指南。
Rheumatology (Oxford). 2010 Jun;49(6):1197-9. doi: 10.1093/rheumatology/keq006a. Epub 2010 Mar 22.
8
[Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].[药物创新的成本效益。肿瘤坏死因子-α拮抗剂治疗类风湿关节炎的卫生经济学方面]
Pharm Unserer Zeit. 2003;32(5):420-5. doi: 10.1002/pauz.200300042.
9
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.类风湿关节炎初始 TNFi 治疗失败后应用替代肿瘤坏死因子抑制剂（TNFi）或阿巴西普或利妥昔单抗：SWITCH RCT。
Health Technol Assess. 2018 Jun;22(34):1-280. doi: 10.3310/hta22340.
10
The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.可溶性肿瘤坏死因子受体依那西普：治疗自身免疫性风湿疾病的新策略。
Drugs Today (Barc). 2004 Apr;40(4):281-324. doi: 10.1358/dot.2004.40.4.820078.

引用本文的文献

1
Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.医疗保险部分 D 中治疗类风湿关节炎的高成本专科药物的覆盖范围。
Arthritis Rheumatol. 2015 Jun;67(6):1474-80. doi: 10.1002/art.39079.
2
The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis.抗 TNF-α 疗法在类风湿关节炎患者中的序贯应用效果：系统评价和荟萃分析。
Rheumatology (Oxford). 2010 Dec;49(12):2313-21. doi: 10.1093/rheumatology/keq169. Epub 2010 Jun 21.
3
Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

本文引用的文献

1
Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort.美国类风湿关节炎队列中肿瘤坏死因子拮抗剂的反应性
Am J Med. 2008 Jun;121(6):532-8. doi: 10.1016/j.amjmed.2008.02.018.
2
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.在对第一种抗TNF药物无反应的患者中，转换抗TNF治疗对健康评估问卷（HAQ）反应的影响。
Rheumatology (Oxford). 2008 Jul;47(7):1000-5. doi: 10.1093/rheumatology/ken127. Epub 2008 Apr 17.
3
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
利用生物疗法在类风湿性关节炎治疗中实现公平竞争：疗效相同则机会均等。
Clin Rheumatol. 2010 Mar;29(3):233-9. doi: 10.1007/s10067-009-1338-1. Epub 2009 Dec 29.
类风湿关节炎中对第二种或第三种肿瘤坏死因子抑制剂的治疗反应：来自瑞典南部关节炎治疗组登记处的结果
Rheumatology (Oxford). 2008 Apr;47(4):507-13. doi: 10.1093/rheumatology/ken034. Epub 2008 Feb 27.
4
Switching anti-TNF-alpha agents: what is the evidence?转换抗肿瘤坏死因子-α药物：有哪些证据？
Curr Rheumatol Rep. 2007 Oct;9(5):416-20. doi: 10.1007/s11926-007-0066-2.
5
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.阿达木单抗在有TNF拮抗剂治疗史的类风湿关节炎患者临床实践中的有效性。
Rheumatology (Oxford). 2007 Jul;46(7):1191-9. doi: 10.1093/rheumatology/kem091. Epub 2007 May 15.
6
Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.类风湿关节炎患者的治疗：英夫利昔单抗治疗失败后改用依那西普的疗效
Arthritis Rheum. 2007 Apr 15;57(3):448-53. doi: 10.1002/art.22617.
7
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.类风湿关节炎患者从一种抗肿瘤坏死因子α药物转换为另一种抗肿瘤坏死因子α药物后的结局：一项大型英国全国队列研究的结果
Arthritis Rheum. 2007 Jan;56(1):13-20. doi: 10.1002/art.22331.
8
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.一项观察性队列研究中肿瘤坏死因子抑制剂在类风湿关节炎中的疗效：根据患者参与主要随机临床试验的资格进行比较
Arthritis Rheum. 2006 Nov;54(11):3399-407. doi: 10.1002/art.22193.
9
Switching tumor necrosis factor inhibitors: an opinion.转换肿瘤坏死因子抑制剂：一种观点。
Nat Clin Pract Rheumatol. 2006 Nov;2(11):576-7. doi: 10.1038/ncprheum0339.
10
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.